相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
3
75.0%
招募中
1
25.0%
暂无批准数据
- A joint GIST and K-Medi Hub research team has been selected for the 2026 National New Drug Development Project to develop small-molecule immuno-oncology drugs targeting the CD73–adenosine pathway. - The three-year project (April 2026–March 2029) aims to inhibit CD73 activity in the tumor microenvironment, enabling immune cells to more effectively recognize and attack cancer cells. - GIST will lead initial candidate compound discovery using medicinal chemistry and structure-based drug design, while K-Medi Hub will validate efficacy and mechanism of action. - The team expects to develop oral small-molecule therapies offering greater convenience and higher combination therapy potential compared to existing injectable antibody treatments.
- University of Florida researchers developed DH20931, an experimental drug that kills triple-negative breast cancer cells by overwhelming them with toxic ceramide lipids through CerS2 enzyme targeting. - The compound significantly slowed tumor growth in mouse models without causing toxicity and enhanced chemotherapy effectiveness by reducing required doxorubicin doses fivefold. - DH20931 employs a dual-pathway mechanism, triggering both lipid accumulation and calcium flooding to disrupt mitochondria and induce cancer cell death. - The drug showed activity against multiple breast cancer subtypes and may have broader applications in other solid tumors due to its multi-pathway approach.
- A South Korean study suggests fecal microbiota transplants (FMTs) may enhance immunotherapy efficacy in gastrointestinal (GI) cancer patients resistant to anti-PD-1 drugs. - The study found that 46.2% of patients with metastatic solid tumors refractory to nivolumab benefited from FMTs, showing tumor shrinkage in some cases. - Specific bacterial strains, like *Prevotella merdae*, improved FMT effectiveness, while others, such as *Lactobacillus salivarius*, had detrimental impacts. - Researchers emphasize the need for efficient FMT production methods and further clinical trials to integrate FMT into standard cancer treatment.
